Epidermal Growth Factors (EGF)

This cell line was derived from ATCC catalog No. CCL-185.

This product is a panel of three (3) genetically modified cell lines involving the EGFR gene. The panel consists of a EGFR knockout cell line (EGFR -/- ) as well as a EGFR low and a EGFR high expression cell line.

This product is a panel of two (2) genetically modified cell lines involving the EGFR gene and the tumor-sepcific EGFRvIII extracellular mutation. The panel consists of a EGFR knockout cell line (EGFR -/- ) and an EGFRvIII high expression cell line.

Airway Epithelial Cell Growth Medium (Ready-to-use) Application Airway Epithelial Cell Growth Medium is a serum-free medium optimized for the in vitro cultivation of epithelial cells from large air passages. The medium is optimized for primary

Airway Epithelial Cell Growth Medium Kit Application Airway Epithelial Cell Growth Medium is a serum-free medium optimized for the in vitro cultivation of epithelial cells from large air passages. The medium is optimized for primary human cells,

Airway Epithelial Cell Basal Medium (supplements sold separately) To form a complete medium, it should be combined with the media supplements: C-39165 or C-39160 Application Airway Epithelial Cell Growth Medium is a serum-free medium optimized for

Airway Epithelial Cell Basal Medium, phenol red-free (supplements sold separately) Application Airway Epithelial Cell Growth Medium is a serum-free medium optimized for the in vitro cultivation of epithelial cells from large air passages. The

Airway Epithelial Cell Growth Medium SupplementPack (basal medium sold separately) To form a complete medium, it should be combined with the basal medium: C-21260 Application Airway Epithelial Cell Growth Medium is a serum-free medium optimized for

Airway Epithelial Cell Growth Medium SupplementMix (basal medium sold separately) To form a complete medium, it should be combined with the basal medium: C-21260 Application Airway Epithelial Cell Growth Medium is a serum-free medium optimized for

EGF-like-domain, multiple 8 (EGFL8), an EGFL7 paralog, is downregulated in metastatic colorectal cancers (CRC) making it a potential prognostic marker for poor prognosis in CRC and advanced gastric cancer. Specificity Anti-EGFL8 polyclonal antibody

Immunogen EGF-like-domain, multiple 8 Application All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the

Immunogen EGF like, fibronectin type III and laminin G domains Application All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive